MedTrace Logo

Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.

NCT07268612 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-12-08

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the safety and clinical benefit of two doses of CYFENDUS vaccine when used with the concurrent recommended antibacterial regimen for post-exposure prophylaxis to prevent inhalational anthrax and/or anthrax meningitis.

Conditions

  • Anthrax

Interventions

BIOLOGICAL

CYFENDUS

Intramuscular administration of two doses of Anthrax Vaccine Adsorbed, Adjuvanted

Sponsors & Collaborators

  • Emergent BioSolutions

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2035-11-30
Primary Completion
2036-11-30
Completion
2037-11-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07268612 on ClinicalTrials.gov